
Studies of changes in the metabolic state (metabonomics) can reflect (biomark) disease pathways, drug action or toxicity. Changes in the metabolic fingerprint can be used to understand the effects of exposure to drugs or toxins, or pinpoint metabolic changes by genetic disorders. To date most studies have relied on profiles in either urine or plasma, which reflect the state of the entire organism. For many pharamacological studies, the effects on specific tissues and possbily differential effects on various tissues are of great interest. Microdialysis provides an approach that enables the profiling of the extracellular fluid of specific tissues of individual subjects over time. Combining biomarker and/or metabonomics approaches with microdialysis sampling in targeted tissues represents a new approach to obtaining pharmacodynamic information. Inherent to the use of microdialysis sampling are the small volume samples with often very low concentrations of compounds of interest. Such samples require sophisticated analytical technologies. This symposium will present state-of-the-art approaches to tissue targeted metabonomic and biomarker studies.
Craig E. Lunte, Ph.D.
University of Kansas
Studying Rat Brain Neurochemistry using Nanoprobe NMR Spectroscopy: A Metabonomics Approach
Alvin C. Bach II, Ph.D.
Wyeth Pharmaceuticals
Metabolic Profiling of the Traumatic Human Brain
Jonas Bergquist, Ph.D.
Uppsala University
Metabolic Profiling of Human Liver Transplant Microdialysates: Amino Acids and 3-Nitrotyrosine
Douglas A. Richards, Ph.D.
University of Birmingham Medical School
Tissue Targeted Metabonomics and Biomarker Approaches to Studying Oxidative Stress
Craig E. Lunte, Ph.D.
University of Kansas
*Session tentatively scheduled to be recorded.
Back to Top
Contact Us | Feedback
© 2007 American Association of Pharmaceutical Scientists www.aapspharmaceutica.com